Eric Dobmeier - Net Worth and Insider Trading

Eric Dobmeier Net Worth

The estimated net worth of Eric Dobmeier is at least $40 Million dollars as of 2024-11-05. Eric Dobmeier is the COO of Seagen Inc and owns about 119,860 shares of Seagen Inc (SGEN) stock worth over $27 Million. Eric Dobmeier is the President, CEO of Chinook Therapeutics Inc and owns about 301,138 shares of Chinook Therapeutics Inc (KDNY) stock worth over $12 Million. Eric Dobmeier is also the Director of Atara Biotherapeutics Inc and owns about 22,533 shares of Atara Biotherapeutics Inc (ATRA) stock worth over $228,710. Besides these, Eric Dobmeier also holds Adaptive Biotechnologies Corp (ADPT) . Details can be seen in Eric Dobmeier's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Eric Dobmeier has not made any transactions after 2023-11-10 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Eric Dobmeier

Eric Dobmeier Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Eric Dobmeier owns 8 companies in total, including Aduro Biotech Inc (ADRO) , Adaptive Biotechnologies Corp (ADPT) , and Atara Biotherapeutics Inc (ATRA) among others .

Click here to see the complete history of Eric Dobmeier’s form 4 insider trades.

Insider Ownership Summary of Eric Dobmeier

Ticker	Comapny	Transaction Date	Type of Owner
ADRO	Aduro Biotech Inc	2020-10-05	director & President & CEO
ADPT	Adaptive Biotechnologies Corp	2021-01-04	director
ATRA	Atara Biotherapeutics Inc	2023-11-10	director
		2017-05-25	director
		2017-12-04	Chief Operating Officer
		2017-06-19	director
		2023-04-24	director & President & CEO
		2023-02-02	director

Eric Dobmeier Latest Holdings Summary

Eric Dobmeier currently owns a total of 4 stocks. Among these stocks, Eric Dobmeier owns 119,860 shares of Seagen Inc (SGEN) as of December 4, 2017, with a value of $27 Million and a weighting of 68.87%. Eric Dobmeier owns 301,138 shares of Chinook Therapeutics Inc (KDNY) as of April 24, 2023, with a value of $12 Million and a weighting of 30.55%. Eric Dobmeier also owns 22,533 shares of Atara Biotherapeutics Inc (ATRA) as of November 10, 2023, with a value of $228,710 and a weighting of 0.57%. The other 1 stocks Adaptive Biotechnologies Corp (ADPT) have a combined weighting of 0% among all his current holdings.

Latest Holdings of Eric Dobmeier

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
SGEN	Seagen Inc	2017-12-04	119,860	228.74	27,416,776
KDNY	Chinook Therapeutics Inc	2023-04-24	301,138	40.39	12,162,964
ATRA	Atara Biotherapeutics Inc	2023-11-10	22,533	10.15	228,710
ADPT	Adaptive Biotechnologies Corp	2021-01-04	0	5.47	0

Holding Weightings of Eric Dobmeier

Eric Dobmeier Form 4 Trading Tracker

According to the SEC Form 4 filings, Eric Dobmeier has made a total of 0 transactions in Seagen Inc (SGEN) over the past 5 years. The most-recent trade in Seagen Inc is the sale of 3,729 shares on December 4, 2017, which brought Eric Dobmeier around $219,079.

According to the SEC Form 4 filings, Eric Dobmeier has made a total of 11 transactions in Chinook Therapeutics Inc (KDNY) over the past 5 years, including 7 buys and 4 sells. The most-recent trade in Chinook Therapeutics Inc is the sale of 25,000 shares on April 24, 2023, which brought Eric Dobmeier around $540,250.

According to the SEC Form 4 filings, Eric Dobmeier has made a total of 1 transactions in Atara Biotherapeutics Inc (ATRA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Atara Biotherapeutics Inc is the acquisition of 17,873 shares on November 10, 2023, which cost Eric Dobmeier around $102,770.

More details on Eric Dobmeier's insider transactions can be found in the Insider Trading History of Eric Dobmeier table.

Insider Trading History of Eric Dobmeier

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Eric Dobmeier Trading Performance

GuruFocus tracks the stock performance after each of Eric Dobmeier's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Eric Dobmeier is 34.23%. GuruFocus also compares Eric Dobmeier's trading performance to market benchmark return within the same time period. The performance of stocks bought by Eric Dobmeier within 3 months outperforms 7 times out of 11 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Eric Dobmeier's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Eric Dobmeier

Average Return

Average return per transaction

Outperforming Transactions

8 out of 11 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	24.84
Relative Return to S&P 500(%)	23.46

Eric Dobmeier Ownership Network

Ownership Network List of Eric Dobmeier

No Data

Ownership Network Relation of Eric Dobmeier

Eric Dobmeier Owned Company Details

What does Aduro Biotech Inc do?

Who are the key executives at Aduro Biotech Inc?

Eric Dobmeier is the director & President & CEO of Aduro Biotech Inc. Other key executives at Aduro Biotech Inc include 10 percent owner Versant Voyageurs I, L.p. , 10 percent owner Versant Voyageurs I Parallel, L.p. , and 10 percent owner Versant Venture Capital Vii, L.p. .

Aduro Biotech Inc (ADRO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aduro Biotech Inc (ADRO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aduro Biotech Inc (ADRO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aduro Biotech Inc (ADRO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aduro Biotech Inc Insider Transactions

No Available Data

What does Adaptive Biotechnologies Corp do?

Who are the key executives at Adaptive Biotechnologies Corp?

Eric Dobmeier is the director of Adaptive Biotechnologies Corp. Other key executives at Adaptive Biotechnologies Corp include SVP and General Counsel Stacy L Taylor , Chief Financial Officer Tycho Peterson , and Principal Accounting Officer Kyle Piskel .

Adaptive Biotechnologies Corp (ADPT) Insider Trades Summary

Over the past 18 months, Eric Dobmeier made no insider transaction in Adaptive Biotechnologies Corp (ADPT). Other recent insider transactions involving Adaptive Biotechnologies Corp (ADPT) include a net sale of 258,417 shares made by Tycho Peterson , a net sale of 40,303 shares made by Stacy L Taylor , and a net sale of 7,986 shares made by Kyle Piskel .

In summary, during the past 3 months, insiders sold 26,922 shares of Adaptive Biotechnologies Corp (ADPT) in total and bought 0 shares, with a net sale of 26,922 shares. During the past 18 months, 467,732 shares of Adaptive Biotechnologies Corp (ADPT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 467,732 shares.

Adaptive Biotechnologies Corp (ADPT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Adaptive Biotechnologies Corp Insider Transactions

No Available Data

What does Atara Biotherapeutics Inc do?

Who are the key executives at Atara Biotherapeutics Inc?

Eric Dobmeier is the director of Atara Biotherapeutics Inc. Other key executives at Atara Biotherapeutics Inc include EVP & Global Head RA & Quality Jill Henrich , SVP & GC & Secretary Amar Murugan , and director & President and CEO Pascal Touchon .

Atara Biotherapeutics Inc (ATRA) Insider Trades Summary

Over the past 18 months, Eric Dobmeier made 1 insider transaction in Atara Biotherapeutics Inc (ATRA) with a net purchase of 446,825. Other recent insider transactions involving Atara Biotherapeutics Inc (ATRA) include a net sale of 204,620 shares made by Pascal Touchon , a net sale of 68,971 shares made by Amar Murugan , and a net sale of 64,459 shares made by Eric J Hyllengren .

In summary, during the past 3 months, insiders sold 8,050 shares of Atara Biotherapeutics Inc (ATRA) in total and bought 0 shares, with a net sale of 8,050 shares. During the past 18 months, 27,448 shares of Atara Biotherapeutics Inc (ATRA) were sold and 32,673 shares were bought by its insiders, resulting in a net purchase of 5,225 shares.

Atara Biotherapeutics Inc (ATRA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Atara Biotherapeutics Inc Insider Transactions

No Available Data

What does Aravive Inc do?

Who are the key executives at Aravive Inc?

Eric Dobmeier is the director of Aravive Inc. Other key executives at Aravive Inc include Chief Commercial Officer Maria Carolina Petrini , Chief Medical Officer Robert B. Geller , and Chief Financial Officer Rudy Howard .

Aravive Inc (ARAV) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aravive Inc (ARAV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aravive Inc (ARAV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aravive Inc (ARAV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aravive Inc Insider Transactions

No Available Data

What does Seagen Inc do?

Who are the key executives at Seagen Inc?

Eric Dobmeier is the Chief Operating Officer of Seagen Inc. Other key executives at Seagen Inc include director & Chief Executive Officer David R Epstein , See Remarks Vaughn B Himes , and EVP & Commercial Charles R Romp .

Seagen Inc (SGEN) Insider Trades Summary

Over the past 18 months, Eric Dobmeier made no insider transaction in Seagen Inc (SGEN). Other recent insider transactions involving Seagen Inc (SGEN) include a net sale of 36,031 shares made by Vaughn B Himes , a net sale of 2,095 shares made by Charles R Romp , and a net sale of 5,116 shares made by Roger D Dansey .

In summary, during the past 3 months, insiders sold 0 shares of Seagen Inc (SGEN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 65,700 shares of Seagen Inc (SGEN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 65,700 shares.

Seagen Inc (SGEN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Seagen Inc Insider Transactions

No Available Data

What does Stemline Therapeutics Inc do?

Who are the key executives at Stemline Therapeutics Inc?

Eric Dobmeier is the director of Stemline Therapeutics Inc. Other key executives at Stemline Therapeutics Inc include Chief Operating Officer Kenneth Hoberman , and Chief Medical Officer Eric K Rowinsky .

Stemline Therapeutics Inc (STML) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Stemline Therapeutics Inc (STML) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Stemline Therapeutics Inc (STML) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Stemline Therapeutics Inc (STML)'s detailed insider trading history can be found in Insider Trading Tracker table.

Stemline Therapeutics Inc Insider Transactions

No Available Data

What does Chinook Therapeutics Inc do?

Who are the key executives at Chinook Therapeutics Inc?

Eric Dobmeier is the director & President & CEO of Chinook Therapeutics Inc. Other key executives at Chinook Therapeutics Inc include Head of Renal Discovery Andrew James King , director & 10 percent owner Davis Jerel , and Chief Commercial Officer Andrew Oxtoby .

Chinook Therapeutics Inc (KDNY) Insider Trades Summary

Over the past 18 months, Eric Dobmeier made no insider transaction in Chinook Therapeutics Inc (KDNY). Other recent insider transactions involving Chinook Therapeutics Inc (KDNY) include a net sale of 1,168 shares made by Andrew James King , and a net sale of 1,155 shares made by William Mariner Greenman .

In summary, during the past 3 months, insiders sold 0 shares of Chinook Therapeutics Inc (KDNY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 2,323 shares of Chinook Therapeutics Inc (KDNY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 2,323 shares.

Chinook Therapeutics Inc (KDNY)'s detailed insider trading history can be found in Insider Trading Tracker table.

Chinook Therapeutics Inc Insider Transactions

No Available Data

What does Structure Therapeutics Inc do?

Who are the key executives at Structure Therapeutics Inc?

Eric Dobmeier is the director of Structure Therapeutics Inc. Other key executives at Structure Therapeutics Inc include other: See Explanation of Responses Biotechnology Value Fund L P , 10 percent owner Bvf Gp Holdings Llc , and other: See Explanation of Responses Bvf Ii Gp Llc .

Structure Therapeutics Inc (GPCR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Structure Therapeutics Inc (GPCR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Structure Therapeutics Inc (GPCR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Structure Therapeutics Inc (GPCR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Structure Therapeutics Inc Insider Transactions

No Available Data

Eric Dobmeier Mailing Address

Above is the net worth, insider trading, and ownership report for Eric Dobmeier. You might contact Eric Dobmeier via mailing address: C/o Saettle Genetics Inc, 21823 30th Drive Se, Bothell Wa 98021.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.